NK Cell Dysfunction and Checkpoint Immunotherapy

NK cells play important roles in the innate immune responses against tumors. The effector function of NK cells relies on the integration of activating and inhibitory signals. Emerging checkpoint receptors and molecules are being revealed to mediate NK cell dysfunction in the tumor microenvironment....

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 1999
Main Authors Bi, Jiacheng, Tian, Zhigang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 21.08.2019
Subjects
checkpoint blockade
immune evasion
immune tolerance
Immunology
inhibitory receptors
regional immunity
checkpoint blockade
immune tolerance
regional immunity
immune evasion
inhibitory receptors
Online AccessGet full text

Cover

More Information
Summary:NK cells play important roles in the innate immune responses against tumors. The effector function of NK cells relies on the integration of activating and inhibitory signals. Emerging checkpoint receptors and molecules are being revealed to mediate NK cell dysfunction in the tumor microenvironment. Inhibition of some NK cell surface checkpoint receptors has displayed the potential to reverse NK cell dysfunction in tumors, and to boost anti-tumor immunity, both in clinical trials (anti-KIR and anti-NKG2A), and in preclinical studies (e.g., anti-TIGIT, and anti-CD96). To fully exploit the potential of NK-based checkpoint immunotherapy, more understanding of the regional features of NK cells in the tumor microenvironment is required. This will provide valuable information regarding the dynamic nature of NK cell immune response against tumors, as well as novel checkpoints or pathways to be targeted. In this Review, we discuss recent advances in the understanding of NK cell dysfunction in tumors, as well as emerging strategies of NK-based checkpoint immunotherapy for tumors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Daniel Olive, Aix Marseille Université, France
Reviewed by: Eric Vivier, INSERM U1104 Centre d'immunologie de Marseille-Luminy, France; Robin Parihar, Baylor College of Medicine, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2019.01999